Tonix presents real-world claims analysis showing persistent opioid prescribing in US fibromyalgia patients

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

TNXP

0.00
  • Tonix Pharmaceuticals presented results at the 2026 ASCP annual meeting from a U.S. real‑world claims analysis of opioid use in adults with fibromyalgia.
  • The study found opioid prescribing remained widespread across insurance types, signaling a persistent clinical burden despite guidelines discouraging opioids for fibromyalgia.
  • Concomitant opioid and benzodiazepine use was also common, underscoring safety and dependence concerns in routine care.
  • The readout supports Tonix’s commercial push for TONMYA, which it launched in November 2025 as a non‑opioid treatment for fibromyalgia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605281630PRIMZONEFULLFEED9728543) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.